Related Experiment Video
Updated: Aug 10, 2026

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
Molecular modeling of the Abeta1-42 peptide from Alzheimer's disease
M O Chaney1, S D Webster, Y M Kuo
1Biotechnology Core, Eli Lilly Research Laboratories, Indianapolis, IN 46285, USA.
Abstract:
The three-dimensional structure of the Alzheimer's disease Abeta1-42 peptide was predicted by sequence homology, threading approaches and by experimental observations. The Abeta molecule displayed a Greek key motif with four antiparallel beta-strands. To shield thermodynamically unfavorable domains, two Abeta molecules interact with each other to generate a beta-barrel structure with a hydrophilic surface and a hydrophobic core. The N-terminal domains of the dimer form crevices into which the non-polar C-termini are accommodated to yield a globular structure 27x32 A in diameter. Alternatively, the C-terminal domains of two opposing dimers could be extended to form an antiparallel beta-sheet. The stacking of these building blocks generates a helical protofilament. To create a thermodynamically more favorable structure, three protofilaments associate into a right-handed triple helix with a hydrophobic beta-sheet completely surrounded by the hydrophilic beta-barrels made of residues 1-28. Two triple helical strands can further associate into a right-handed amyloid filament. Although our model did not meet all the expected criteria, it nevertheless exhibited a series of naturally disposed structural features, revealed by other biophysical studies utilizing synthetic Abeta peptides. These characteristics are of functional significance in terms of Abeta-topology, fibril formation and cytotoxicity. The model also suggests that Abeta may not exist in a thermodynamically stable conformation, but rather as an ensemble of metastable dimeric structures some of which are capable of generating an extended C-terminal antiparallel beta-sheet essential in the promotion of fibrillogenesis.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology

